Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2026Journal of Clinical Oncology

Development of human B7H3/IL13Ra2 bispecific armored CAR-T for treatment of glioblastoma.

View Full Paper
Ask AI
Bookmark
Share

Authors

KZKeming ZhangNJNing JiangCZCharles Zhao

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates anti-tumor effects of EPC-003 in glioblastoma, indicating promising safety and efficacy.

Key Points

  • The aim is to develop a bispecific CAR-T cell therapy targeting glioblastoma with enhanced anti-tumor efficacy and safety.
  • Developed EPC-003, a bispecific CAR-T targeting IL13Ra2 and B7-H3 with a multi-mechanism armor.
  • Utilized proprietary mRNA display platform to identify human anti-IL13Ra2 and anti-B7-H3 scFvs.
  • Evaluated efficacy and safety in orthotopic glioblastoma models with intracranial CAR-T cell administration.
  • EPC-003 induced tumor regression in a dose-dependent manner, with two doses evaluated (0.4 × 10⁶ and 1.2 × 10⁶ CAR-T cells).
  • Demonstrated a favorable safety profile with no significant side effects in preclinical toxicity studies across 25 organs.
  • Enriched CAR-T product contained >65% central memory T-cells, enhancing potential for sustained anti-tumor activity.

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6a192ee7fab5b468c441824dhttps://doi.org/10.1200/jco.2026.44.16_suppl.2056
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multi-mechanism armored B7H3/IL13Ra2 bispecific CAR-T for treatment of glioblastoma.2026
  2. 2Safety and efficacy of B7H3/IL13Rα2 bispecific armored CAR-T for treatment of recurrent/refractory glioblastoma.2026
  3. 3B7H3/IL13Rα2 bispecific armored CAR-T for recurrent/refractory glioblastoma: Safety, efficacy, and immune dynamics.2026
  4. 4Safety and efficacy of B7-H3 targeting CAR-T cell therapy for patients with recurrent GBM.2024 · 21 citations
  5. 5IMMU-72. Locoregionally delivered PD-1 blockade augments B7-H3 targeting CAR T cell efficacy in models of glioblastoma2025